Neelakantan et al., NNMT inhibition reverses diet-induced obesity in mice (2018) Babula et al., NNMT inhibition mitigates obesity-related metabolic dysfunction: fat mass, glucose tolerance, hepatic steatosis, pharmacokinetics and off-target screen (Diabetes Obes Metab, 2024) Dimet-Wiley et al., NNMT inhibition mimics and boosts exercise-mediated muscle improvements in aged mice (Sci Rep, 2024) NNMT inhibition and muscle function in aged mice (2019) Reduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in DIO mice (2022): the diet-switch combination study Awosemo et al., rat pharmacokinetics of 5-amino-1MQ (2021) NNMT in metabolism and disease: review Sigma-Aldrich: 5-Amino-1MQ iodide product data (CAS 42464-96-0) FDA: bulk drug substances used in compounding under section 503A Disclaimer: Informational and research purposes only, not medical advice
.png)
Weiss assumes responsibility for providing optimal, safe, and ethical care to study participants and clinical support toward the TAMB mission conducting inpatient and outpatient proof-of-concept human laboratory studies
To view or add a comment, sign in More Relevant Posts - : The GLP-1 Market is rapidly expanding as innovative therapies redefine the treatment of obesity, type 2 diabetes, and other metabolic disorders, creating one of the most competitive segments in the pharmaceutical industry
Dual agonists reduce appetite, making it tempting to skip meals or eat minimally, but inadequate protein accelerates muscle loss